Cosela
Total Payments
$2.3M
Transactions
415
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2.3M | 415 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 415 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| G1T28-207 | G1 Therapeutics, Inc. | $1.5M | 1 |
| A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) | G1 Therapeutics, Inc. | $388,790 | 1 |
| A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4) | G1 Therapeutics, Inc. | $233,807 | 2 |
| A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3) | G1 Therapeutics, Inc. | $67,896 | 1 |
| G1T28-113 | G1 Therapeutics, Inc. | $56,131 | 0 |
| Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive Stage Small Cell Lung Cancer | G1 Therapeutics, Inc. | $21,199 | 0 |
| G1T48-01 | G1 Therapeutics, Inc. | $5,396 | 0 |
Top Doctors Receiving Payments for Cosela
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $2.2M | 403 |
| , M.D | Hematology & Oncology | Gettysburg, PA | $120,268 | 9 |
| , MD | Student in an Organized Health Care Education/Training Program | Durham, NC | $3,125 | 1 |
| , MD | Medical Oncology | New York, NY | $1,000 | 1 |
| Peter O Donnell | Internal Medicine | Chicago, IL | $962.50 | 1 |
Ad
Manufacturing Companies
- G1 Therapeutics, Inc. $2.3M
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 4
- Transactions 415
About Cosela
Cosela is a drug associated with $2.3M in payments to 4 healthcare providers, recorded across 415 transactions in the CMS Open Payments database. The primary manufacturer is G1 Therapeutics, Inc..
Payment data is available from 2021 to 2021. In 2021, $2.3M was paid across 415 transactions to 4 doctors.
The most common payment nature for Cosela is "Unspecified" ($2.3M, 100.0% of total).
Cosela is associated with 7 research studies, including "G1T28-207" ($1.5M).